CLVS - CLVS STOCK NEWS

Clovis Oncology reported $148.8 million in global net revenues for Rubraca in 2021, a 10% decline from 2020. Q4 2021 revenues were $36.0 million, down 5% from Q3 and 17% year-over-year due to the impact of COVID-19 on ovarian cancer diagnoses. The company anticipates three Phase 3 data read-outs in 2022 that could significantly expand Rubraca's market potential. R&D and SG&A expenses decreased significantly in FY 2021, helping reduce cash burn. Clovis ended 2021 with $143.4 million in cash and equivalents.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and year-end 2021 financial results on February 23, 2022, before the US markets open. A conference call will be held at 8:30 AM ET to discuss the details. The call will be available via webcast, with a replay accessible for 30 days. Clovis is dedicated to developing innovative anti-cancer agents and provides diagnostic tools targeting specific cancer populations.

Clovis Oncology announced preliminary, unaudited global product revenues for Q4 and FY 2021, estimating $35.5M - $36.1M in Q4 sales of Rubraca compared to $37.9M in Q3 2021 and $43.3M for Q4 2020. Total FY 2021 revenues are $148.3M - $148.9M, down from $164.5M in FY 2020. The ongoing impact of COVID-19 on ovarian cancer diagnoses has adversely affected sales. Clovis will present at the J.P. Morgan Healthcare Conference on January 12 and report full financial results on February 23.

Clovis Oncology, Inc. (NASDAQ: CLVS) presented at the 3rd Targeted Radiopharmaceuticals Summit on December 7-9, 2021. Dr. Andrew D. Simmons highlighted FAP-2286, the lead candidate in their targeted radionuclide therapy program, which targets fibroblast activation protein (FAP) in solid tumors. The ongoing Phase 1/2 LuMIERE study is currently enrolling patients, with initial data expected in 2022. Clovis aims to lead in targeted radiopharmaceuticals, reflecting growing clinician enthusiasm in this area.

Clovis Oncology reported Q3 2021 net product revenues of $37.9M for Rubraca, a 3% increase from Q2 but a 2% decrease year-over-year, attributed to fewer ovarian cancer diagnoses due to COVID-19. The company plans three critical Phase 3 data readouts in 2022 to expand Rubraca's patient base. Clovis improved its balance sheet by raising $41.5M through an equity offering and retiring $64.4M in notes. Cost reductions led to a 27% decrease in R&D expenses, while the net loss was $67.4M, down from $78.7M in Q3 2020.

Clovis Oncology, Inc. (NASDAQ: CLVS) will report its third quarter 2021 financial results on November 3, 2021, before US markets open. Following the announcement, senior management will host a conference call and live audio webcast at 8:30 am ET to detail the results. Interested parties can access the webcast on the company's website, with a replay available for 30 days. Clovis Oncology is focused on developing innovative anti-cancer agents and solutions targeting specific cancer populations in the US and international markets.

Clovis Oncology (NASDAQ: CLVS) has signed a clinical supply agreement with ITM Isotope Technologies Munich SE to provide no-carrier-added Lutetium-177 for the development of Clovis' FAP-2286, a first-in-class peptide-targeted radionuclide therapy. The agreement, set for an initial five-year term, aims to secure a long-term supply of this critical isotope for FAP-2286’s clinical trials, which are currently underway in the Phase 1/2 LuMIERE study for patients with advanced solid tumors. This collaboration emphasizes Clovis' commitment to advancing its targeted radionuclide therapy initiatives.

ITM Isotope Technologies Munich SE has signed a clinical supply agreement with Clovis Oncology (NASDAQ: CLVS) to provide its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of FAP-2286. This peptide-targeted radionuclide therapy candidate focuses on advanced solid tumors and is currently in the Phase 1/2 LuMIERE study. The five-year agreement underscores Clovis's commitment to ensuring a long-term supply of essential radioisotopes for its targeted therapies.

Clovis Oncology (NASDAQ: CLVS) presented new nonclinical data on FAP-2286, a peptide-targeted radionuclide therapy, at the AACR-NCI-EORTC Virtual Conference from October 7-10, 2021. The study revealed high expression of fibroblast activating protein (FAP) in 9 out of 16 solid tumor types, including pancreatic and colon cancers. The Phase 1/2 LuMIERE trial is underway, focusing on patients with FAP-positive solid tumors. Approval for FAP-2286's clinical use could address significant cancer treatment gaps, potentially positioning Clovis as a leader in targeted radionuclide therapy.